Pulse Biosciences, Inc. (PLSE)
Automate Your Wheel Strategy on PLSE
With Tiblio's Option Bot, you can configure your own wheel strategy including PLSE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PLSE
- Rev/Share 0.0247
- Book/Share 1.5531
- PB 11.4931
- Debt/Equity 0.0789
- CurrentRatio 12.0472
- ROIC -0.6408
- MktCap 1200714504.0
- FreeCF/Share -0.6649
- PFCF -26.8406
- PE -17.6527
- Debt/Assets 0.0686
- DivYield 0
- ROE -0.6527
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PLSE | Oppenheimer | -- | Outperform | -- | $22 | July 7, 2025 |
News
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.
Read More
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: September 17, 2025 by: Business Wire
Sentiment: Neutral
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to four new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awar.
Read More
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive
PLSE wins FDA IDE approval for its NANOCLAMP AF study, advancing nsPFA tech as a novel option in atrial fibrillation surgery.
Read More
PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Pulse Biosciences shares rise on first-in-human study showing its nsPFA tech cuts thyroid nodule size with strong safety and efficacy.
Read More
About Pulse Biosciences, Inc. (PLSE)
- IPO Date 2016-05-18
- Website https://www.pulsebiosciences.com
- Industry Medical - Instruments & Supplies
- CEO Paul Arthur LaViolette
- Employees 75